What is Accelus?
Accelus is globally recognized for its pioneering work in expandable spinal implant technology. The company is dedicated to enhancing surgical procedures and improving patient outcomes through its innovative spinal solutions. A core focus of Accelus's commitment to excellence lies in its advanced Adaptive Geometry technologies, which are specifically engineered for a range of spinal surgeries including transforaminal lumbar interbody fusion (TLIF), posterior lumbar interbody fusion (PLIF), endoscopic-assisted, percutaneous, and lateral spine surgeries. This strategic focus positions Accelus at the forefront of spinal fusion innovation.
How much funding has Accelus raised?
Accelus has raised a total of $32M across 2 funding rounds:
Series D
$12M
Debt
$20M
Series D (2022): $12M with participation from Concord Health Partners
Debt (2024): $20M led by Symbiotic Capital
Key Investors in Accelus
Concord Health Partners
Concord Health Partners is a firm that focuses on the healthcare sector, likely investing in companies that offer innovative solutions to improve medical procedures and patient care, aligning with Accelus's mission in spinal technology.
Symbiotic Capital
Symbiotic Capital is an investment entity that appears to provide capital for companies, potentially focusing on strategic partnerships and growth financing within the healthcare or technology sectors.
What's next for Accelus?
With its recent major enterprise-level funding, Accelus is poised for significant growth and further development of its innovative spinal implant technologies. The company's trajectory suggests a focus on scaling its operations, expanding market reach, and continuing its research and development into advanced Adaptive Geometry solutions. This strategic investment will likely fuel the enhancement of surgical procedures and patient outcomes, reinforcing Accelus's position as a key player in the medical device sector, particularly within spinal fusion technologies.
See full Accelus company page
